Biological
Sibeprenlimab
Sibeprenlimab is a biological therapy with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Active, not recruiting1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
active_not_recruiting133%
completed133%
recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
active_not_recruitingphase_2
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT06928142
completedphase_1
Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject
NCT07105124
recruitingphase_2
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
NCT06740526
Clinical Trials (3)
Showing 3 of 3 trials
NCT06928142Phase 2
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT07105124Phase 1
Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject
NCT06740526Phase 2
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3